Immuneering Corp. Class A (IMRX)
NASDAQ:IMRX
Want to see IMRX full AI Analyst Report?
Atebimetinib, Gnp, Mgnp
Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma (Pdac), Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic, Pdac, Pancreatic Cancer Metastatic, Pdac - Pancreatic Ductal Adenocarcinoma
Phase III
Recruiting
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Apr 20, 2026
―
Imm-6-415
Pancreas Adenocarcinoma, Non-small Cell Lung Cancer, Advanced Solid Tumor (Phase 1), Malignant Melanoma (Cutaneous)
Phase I/II
Completed
A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors
Jan 05, 2024
―
Imm-1-104 Monotherapy, Imm-1-104 + Modified Gemcitabine/Nab-Paclitaxel, Imm-1-104 + Modified Folfirinox, Imm-1-104 + Dabrafenib, Imm-1-104 + Pembrolizumab
Advanced Solid Tumor, Non-Small Cell Lung Cancer (Nsclc), Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous)
Phase I/II
Active Not Recruiting
A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
Oct 14, 2022
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Immuneering Corp. Class A (IMRX) have in its pipeline
IMRX is currently developing the following drugs: Atebimetinib, Gnp, Mgnp, Imm-6-415, Imm-1-104 Monotherapy, Imm-1-104 + Modified Gemcitabine/Nab-Paclitaxel, Imm-1-104 + Modified Folfirinox, Imm-1-104 + Dabrafenib, Imm-1-104 + Pembrolizumab. These drug candidates are in various stages of clinical development as the company works toward FDA approval.